These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38864423)

  • 1. An overview of the efficacy and safety of brexpiprazole for the treatment of schizophrenia in adolescents.
    Crump CJ; Abuelazm H; Ibrahim K; Shah S; El-Mallakh RS
    Expert Rev Neurother; 2024 Aug; 24(8):727-733. PubMed ID: 38864423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
    Kane JM; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Correll CU
    Schizophr Res; 2016 Jul; 174(1-3):93-98. PubMed ID: 27188270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brexpiprazole for the treatment of schizophrenia.
    Hsu WY; Lane HY; Lin CH
    Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric Extrapolation Approach for U.S. Food and Drug Administration Approval of Brexpiprazole in Patients Aged 13 to 17 Years with Schizophrenia.
    Zhang H; Liu J; Sharma V; Zhuang L; Horn P; Uppoor R; Mehta M; Zhu H
    J Clin Pharmacol; 2024 Jul; 64(7):771-778. PubMed ID: 38488344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.
    Fleischhacker WW; Hobart M; Ouyang J; Forbes A; Pfister S; McQuade RD; Carson WH; Sanchez R; Nyilas M; Weiller E
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):11-21. PubMed ID: 27566723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brexpiprazole: A Review in Schizophrenia.
    Frampton JE
    Drugs; 2019 Feb; 79(2):189-200. PubMed ID: 30671869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brexpiprazole.
    Markovic M; Gallipani A; Patel KH; Maroney M
    Ann Pharmacother; 2017 Apr; 51(4):315-322. PubMed ID: 28228056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study.
    Ishigooka J; Iwashita S; Tadori Y
    Psychiatry Clin Neurosci; 2018 Sep; 72(9):692-700. PubMed ID: 29774628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (Secondary Publication).
    Ishigooka J; Usami T; Iwashita S; Kojima Y; Matsuo S
    Neuropsychopharmacol Rep; 2020 Jun; 40(2):122-129. PubMed ID: 32297486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of brexpiprazole - a new antipsychotic drug from the group of dopamine D2 receptor partial agonists.
    Bieńkowski P; Wichniak A
    Psychiatr Pol; 2024 Apr; 58(2):237-248. PubMed ID: 39003508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Brexpiprazole for treatment of schizophrenia: a critical literature study].
    Spoelstra SK; Baas CAJ; Knegtering H
    Tijdschr Psychiatr; 2021; 63(1):48-55. PubMed ID: 33537974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brexpiprazole for the treatment of schizophrenia.
    Yee A
    Expert Rev Neurother; 2016; 16(2):109-22. PubMed ID: 26650624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.
    Marder SR; Hakala MJ; Josiassen MK; Zhang P; Ouyang J; Weiller E; Weiss C; Hobart M
    Acta Neuropsychiatr; 2017 Oct; 29(5):278-290. PubMed ID: 27846922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic Analysis of Brexpiprazole to Support its Indication and Dose Selection in Adolescents With Schizophrenia.
    Wang Y; Wang X; Larsen F; Cahill D; Zoubroulis A; Ward C; Kohegyi E; Raoufinia A
    J Clin Pharmacol; 2023 Nov; 63(11):1290-1299. PubMed ID: 37461192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.
    Stummer L; Markovic M; Maroney M
    Neurodegener Dis Manag; 2020 Aug; 10(4):205-217. PubMed ID: 32618483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brexpiprazole: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2016 Apr; 30(4):335-42. PubMed ID: 27023789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brexpiprazole for treatment-resistant major depressive disorder.
    Fornaro M; Fusco A; Anastasia A; Cattaneo CI; De Berardis D
    Expert Opin Pharmacother; 2019 Nov; 20(16):1925-1933. PubMed ID: 31431092
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.
    Corponi F; Fabbri C; Bitter I; Montgomery S; Vieta E; Kasper S; Pallanti S; Serretti A
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):971-985. PubMed ID: 31255396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
    McEvoy J; Citrome L
    Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.